muscular dystrophy

Pharmalot By Ed Silverman

FDA confirms that critic of Sarepta drug has left the agency

Business By Associated Press

Post-telethon, Muscular Dystrophy Association tries to find its footing

Pharmalot By Ed Silverman

Wall Street betting intensifies over Sarepta’s muscular dystrophy drug

First Opinion By Christopher Anselmo

How a blood test changed my life and helped me become a rare disease advocate